However, the current understanding of glucagon-like peptide-1 actions in renal pathways is inadequate. In rodent and human kidneys, GLP-1 receptors are present in vascular smooth muscles rather ...

Glucagon-Like-Peptide-1 Agonists, like Ozempic, have become extremely popular for weight loss. Here are some of the side ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

The incretin hormone glucagon-like peptide 1 (GLP-1), as well as GLP-1 analogues that are now being used for the treatment of patients with type 2 diabetes, potently suppresses α-cell secretion.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a leading treatment in the fields of diabetes and obesity, with recent preclinical and clinical studies indicating significant ...

As of 2021–2022, approximately 74% of U.S. adults aged 20 and older were classified as overweight or obese, with 42.1% meeting criteria for obesity alone, according to the Centers for Disease ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Nauck MA, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest.

THURSDAY, Nov. 21, 2024 (HealthDay News) -- Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study ...

Glucagon-like peptide-1 receptor agonists during pregnancy and lactation. Jonathan S. Zipursky, Tali Bogler and Cynthia Maxwell. CMAJ December 16, 2024 196 ... However, given a paucity of human data ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a ...